Dr. Mansukh Mandaviya, the union health minister, writes that it is “a significant boost to India’s fight against COVID-19.”
According to Union Health Minister Dr. Mansukh Mandaviya, a nasal vaccination against Covid-19 created by Bharat Biotech has been given the drug controller’s approval for “limited use” among adults “in emergency situations.”
Under PM Narendra Modi’s leadership, “India has harnessed its science, research and development, and people resources,” the minister claimed.
As the first anti-Covid medication in the nation, Mumbai-based Glenmark and SaNOtize released a nasal spray for adult patients in February under the brand name FabiSpray.
As part of an expedited clearance procedure, the business received manufacturing and marketing permissions from the Drugs Controller General of India for its nitric oxide nasal spray.
The official release read, “Phase 3 study in India met the primary endpoints and exhibited reduction of viral load of 94% in 24 hours and 994% in 48 hours.”
According to government data updated at 8 am on Tuesday, India reported a one-day increase of 4,417 coronavirus infections, which is the lowest in three months.
There were 23 recorded fatalities while there were 52,336 fewer active Covid cases.
According to the Health Ministry, the number of current cases now makes up 0.12% of all infections, while the recovery rate has grown to 98.69%.
Worldwide, the development of vaccines is also gaining momentum. The Omicron and original strains of the virus will be targeted by a second “bivalent” vaccination that the UK health authorities approved on Saturday.